Summary Statement
Background & objectives: Psoriasis is a chronic inflammatory T-lymphocyte-mediated disease. The main objectives of this study were to evaluate the clinical efficacy of narrowband ultraviolet B (NB-UVB) phototherapy in treating chronic plaque psoriasis (CPP) and to examine its effect on the peripheral blood levels of various T-lymphocyte subpopulations.
Results: Peripheral blood levels of CD3+CD4+CD25+ T-lymphocytes were significantly increased, whereas those of CD3-CD56+ and CD3-CD16+CD56+ NK cells were virtually significantly decreased.
Conclusions & implications:
Alterations in peripheral blood levels of CD4+CD25+ T lymphocytes, and possibly CD3-CD56+ and CD3-CD16+CD56+ NK cells, might be used as efficacy parameters for NB-UVB phototherapy of CPP. 
Introduction
Psoriasis (derived from the Hellenic word "psora" for itching) is a chronic inflammatory cutaneous disease affecting approximately 1-3% of the global population. [1] [2] [3] [4] The aetiology of psoriasis is not completely understood and the disease was originally considered to be primarily a keratinization disorder of the skin, caused by keratinocyte hyperproliferation associated with abnormal epidermal differentiation. 5 Over the latest years, the theory on the aetiopathogenesis of psoriasis has substantially changed and it is now recognized that immunity -probably autoimmunity-plays a significant role in the development of psoriasis. 6, 7 Specifically, psoriasis is a T-lymphocyte-mediated disease, histologically characterized by localized inflammation induced by the immune system. 7, 8 In the inflammatory infiltrate, cluster of differentiation 4+ (CD4+) T lymphocytes predominate within the dermis and CD8+ T lymphocytes localize mainly in the epidermis. 9 Several T-lymphocyte subsets (CD4+, CD8+, CD45RO+, CD45RA+ and others) seem to play a primary role in the pathogenesis of psoriasis; recently, natural killer cells (NK cells) and natural killer/T cells (NK/T cells) have also been involved in the development of psoriasis. 10 Ultraviolet irradiation is known to suppress the immune system and reduce inflammatory responses. 11 Narrow-band ultraviolet B radiation (NB-UVB) is an ultraviolet radiation with a wavelength of 311 nm ± 2 nm and in the late 1980s the clinical use of NB-UVB was introduced as an effective method for the phototherapy of psoriasis and other cutaneous conditions, such as eczema or atopic dermatitis. [12] [13] [14] [15] [16] [17] [18] Currently, a series of issues still remain unclear in the literature. It is not known whether psoriatic patients differ from non-psoriatic individuals in the peripheral blood levels of NK and NK/T cells or other T-lymphocyte subpopulations that can be present in psoriatic lesions and be involved in the disease inflammatory response, such as 
CD3+CLA+ cells or T-regulatory subpopulations (CD4+CD25+, CD8+CD25+). This issue
could be related to disease pathogenesis or treatment. The effect of NB-UVB phototherapy on the levels of various T-lymphocyte subpopulations in the peripheral blood of psoriatic patients has also not been clarified.
On the basis of these considerations, the objectives of the present study were to evaluate the efficacy of NB-UVB phototherapy in the treatment of patients with active chronic plaque psoriasis, as clinically revealed by the area (extent) and the severity of psoriatic lesions, 19 as well as to examine the effect of NB-UVB phototherapy on the levels of various T-lymphocyte subpopulations (CD3+, CD4+, CD8+ T lymphocytes, NK/T cells (CD3+CD16+, CD3+CD56+ or CD3+CD16+CD56+), NK cells (CD3-CD16+, CD3-CD56+ or CD3-CD16+CD56+), CD3+CLA+, CD3+CD8+CLA+, CD3+CD4+CD25+ and CD3+CD8+CD25+ T lymphocytes) in the peripheral blood of patients with active chronic plaque psoriasis. Finally, the third study objective was to examine whether the potential alterations in the peripheral blood levels of the above-mentioned T-lymphocyte subpopulations after NB-UVB phototherapy in patients with active chronic plaque psoriasis could be used as therapeutic outcome measures and immunological parameters for assessing the efficacy of NB-UVB phototherapy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 history of psoriasis of any form in the past. The selection of the population of the study was performed on the basis of the following inclusion / exclusion criteria, determined before the initiation of the study.
Inclusion criteria
Study participants ought to be Caucasian volunteers aged ≥18 years. Patients included in the test group ought to be diagnosed with active chronic plaque psoriasis (determined solely on the basis of the clinical appearance of patients, i.e. the presence of papules or red plaques on the epidermis, covered by a silvery scale). Subjects enrolled in the control group ought not to present active psoriasis of any form or a history of psoriasis of any form in the past. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Patients presenting absolute contraindications for NB-UVB phototherapy, such as xeroderma pigmentosum or lupus erythematosus, 18 ought to be excluded from the study.
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Furthermore, patients subjected to any systemic therapy for at least four weeks or any topical therapy throughout the last two weeks of the four-week period of the treatment of active chronic plaque psoriasis also ought to be excluded from the study.
Screening examination (Tables 1 and 2)
A screening examination was carried out during the initial visit of volunteers. For each subject, a medical history was recorded (Table 1) . In each patient in the test group, the area (extent) and the severity of psoriatic lesions were assessed by the degree of erythema, inflammatory infiltration and disquamation, and calculated using the Psoriasis Area and Severity Index (PASI; Table 2 ). PASI scores range from zero (no disease) to 72 (maximum disease area and severity). 19 Patients in the test group presented PASI scores ranging from 8.2 to 25.8 before treatment. Patients with a PASI score >12 were considered to exhibit moderate to severe active chronic plaque psoriasis. In each patient in the test group, calculation of PASI was repeated after the completion of the treatment of active chronic plaque psoriasis (Table 2) .
Flow cytometric immunophenotypical analysis of peripheral blood T lymphocytes
A first peripheral blood sample was collected from the antecubital vein of each patient in the test group immediately before the initiation of treatment of active chronic plaque psoriasis, and a second peripheral blood sample was obtained immediately after the completion of treatment. In the control group, only one peripheral blood sample was collected per subject. The peripheral blood specimens were collected in 2.5 ml tubes For each subject, two tubes were used for sampling. The first tube was used for blood cell count and the second one was employed for flow cytometric immunophenotypical analysis.
In particular, for the first tube monoclonal antibodies against human antigens, namely PERCP-conjugated anti-CD3, PE-Cy7-conjugated anti-CD4, APC-Cy7-conjugated anti-CD8 and FITC-conjugated anti-CLA were used, whereas for the second tube PERCP- 
Therapeutic interventions
Patients in the test group were treated with NB-UVB phototherapy that was initiated in the Photobiologic Department of the Venereal and Skin Diseases Hospital "Andreas Syggros", Athens, Greece during the first week after blood sampling, using a full-body ultraviolet therapy system (UV 5001 BL, Herbert Waldmann GmbH & Co. KG, Villingen-Schwenningen, Germany), equipped with 24 TL01 radiators operating at 100 W (F85/100W-01) for NB-UVB phototherapy. NB-UVB phototherapy was performed for three days weekly 20, 21 throughout four weeks, using an initial NB-UVB radiation dosage of 0.1-0.4 J/cm 2 (depending on the skin type of each patient) that gradually increased during the four-week treatment period. During this gradual increase, each dosage was 20% higher than the preceding one, according to the instructions of the manufacturer. For each patient, 12 dosages were applied in total. NB-UVB radiation was being emitted at a distance of 21 cm from the patient and at a temperature of 20°C. During the operation of the full-body ultraviolet therapy system, all patients were wearing safety glasses and the sensible parts of their body (genitalia) were covered.
In all patients, NB-UVB phototherapy was performed by the same specially-trained nurse, following the instructions of the manufacturer. The aforementioned full-body ultraviolet therapy system was being calibrated every week by a technician of the Venereal and Skin Diseases Hospital "Andreas Syggros" and annually by the above-mentioned manufacturer. TL01 radiators are continually being substituted every two years. 
Study outcome variables
The outcome variables of the study were the mean change in PASI scores after NB- 
Statistical analysis
Quantitative data were expressed as mean value ± standard deviation (when they followed the normal distribution) or as median and interquartile range (when they did not follow the normal distribution), while categorical data were expressed using their frequency (percentage). The subject was used as the statistical unit. The KolmogorovSmirnov test was used to evaluate the normality of data.
Inter-group (test versus control group) statistical comparisons of variables before treatment were performed using the independent samples t-test (in case of data normality), the Welch's t-test (in case of unequal variances of samples) or the Mann-Whitney U test (in case of absence of data normality).
In the test group, intra-group (before versus after treatment) statistical comparisons of variables were performed using the paired samples t-test (in case of data normality) or the Wilcoxon test (in case of absence of data normality).
All statistical tests were two-sided and the differences were considered to be statistically significant, when p<0.05. The statistical analysis was performed using 
Results

Safety of study population
All 30 participants safely completed the study, without any complications / adverse events.
Baseline comparability of study groups (Table 3)
No statistically significant difference (p>0.05) in the peripheral blood levels of all T-lymphocyte subpopulations examined (CD3+, CD4+, CD8+ T lymphocytes, NK/T cells (CD3+CD16+, CD3+CD56+ or CD3+CD16+CD56+), NK cells (CD3-CD16+, CD3-CD56+ or CD3-CD16+CD56+), CD3+CLA+, CD3+CD8+CLA+, CD3+CD4+CD25+ and CD3+CD8+CD25+ T lymphocytes) was revealed between the test and control group (Table 3) . (Table 4 and Fig. 1) In the test group, mean PASI score after NB-UVB phototherapy of active chronic plaque psoriasis was highly statistically significantly lower than that before NB-UVB phototherapy (p<0.0005; Table 4 ). It is noteworthy that the highest PASI score after NB-UVB phototherapy was 8.9 in a patient and therefore in all 20 patients in the test group the PASI scores were <12 after NB-UVB phototherapy, in contrast to the PASI scores before Table 4 ).
Effect of NB-UVB phototherapy on peripheral blood levels of various T-lymphocyte subpopulations
In contrast, the peripheral blood levels of CD3+CD4+CD25+ T lymphocytes were statistically significantly higher after than before NB-UVB phototherapy in the test group (p=0.037<0.05; Table 4 and Fig. 1 ).
Results of statistical analysis for patients with moderate to severe active chronic plaque psoriasis (PASI score >12)
The statistical analysis was repeated specifically for patients with moderate to severe active chronic plaque psoriasis (PASI score >12) and the obtained results as a rule remained unaltered, with only sporadic minor exceptions.
In particular, for patients with moderate to severe active chronic plaque psoriasis (PASI score >12) in the test group, the peripheral blood levels of CD3-CD56+ and CD3-CD16+CD56+ NK cells were clearly not statistically significantly decreased after than before NB-UVB phototherapy (p=0.396 and p=0.518, respectively). In contrast, for the Table 4 ).
In another case, for patients with moderate to severe active chronic plaque psoriasis (PASI score >12) in the test group, the peripheral blood levels of CD3+CLA+ cells were marginally statistically significantly lower than the corresponding levels in the control group, when a parametrical test (independent samples t-test) was used (p=0.043). In contrast, for the entire pool of patients in the test group (i.e. with active chronic plaque psoriasis of any severity and any PASI score), the peripheral blood levels of CD3+CLA+ cells were marginally not statistically significantly different from the corresponding levels in the control group, when the same parametrical test (independent samples t-test) was used (p=0.056; Table 4), whereas the peripheral blood levels of the same cells were marginally statistically significantly lower in the test group before NB-UVB phototherapy than in the control group, when a non-parametrical test (Mann-Whitney U test) was used (p=0.042; Table 4 ).
Discussion
The present study documented the clinical efficacy of NB-UVB phototherapy in the treatment of patients with active chronic plaque psoriasis. This principal finding is in agreement with previous results reported in the literature. In a comparative study, in which psoriatic lesions were irradiated daily with UVB of 254 nm, 280 nm, 290 nm, 296 nm, 300 nm, 304 nm and 313 nm wavelengths, no clearance of psoriasis occurred by the use of wavelengths ≤290 nm, whereas clearance was achieved using wavelengths of 296-313 nm 22 A meta-analysis of randomized and non-randomized controlled studies concluded that NB-UVB is significantly more efficacious than broad-band UVB (wavelength <290 nm) in the phototherapy of psoriasis. 23 It is known that CD4+CD25+ T lymphocytes are involved in the maintenance of natural self-tolerance by reducing immune responses against self-and non-self-antigens, possibly during the stage of T-lymphocyte activation. 24 In contrast, the reduction or eradication of CD4+CD25+ T lymphocytes enhances immune responses against non-self antigens, but could also induce autoimmune responses against specific self-antigens and therefore be a potential aetiological agent of autoimmune diseases, such as rheumatoid arthritis, thyroiditis, gastritis and others. [24] [25] [26] Overall, these studies revealed that CD4+CD25+ T lymphocytes are regulatory T lymphocytes. 27 Nowadays, extensive and robust evidence has demonstrated that CD4+CD25+ regulatory T lymphocytes are highly important in the prevention of autoimmune responses and that the absence of regulatory T lymphocytes expressing CD4, CD25 and the transcription factor forkhead box protein 3 (FOXP3) results in severe autoimmune response in both mice and humans. [27] [28] [29] Consequently, it appears reasonable to anticipate that an efficacious treatment of active chronic plaque psoriasis would result in a reduction of T-lymphocyte-mediated autoimmune responses, which are compatible with an increase in the peripheral blood levels of CD3+CD4+CD25+ T lymphocytes induced by treatment. This plausible hypothesis was confirmed in the present study, in which the peripheral blood levels of CD3+CD4+CD25+ T lymphocytes were statistically significantly higher after than before NB-UVB phototherapy.
However, conflicting findings have been reported in the literature. In an ex vivo study, the exposure of T lymphocytes to low-dose (10 mJ/cm 2 ) UVB resulted in a reduction in the expression of CD25. 30 Another previous study demonstrated that peripheral blood CD25 were elevated (both in percentage and absolute number) in psoriatic patients, compared with non-psoriatic subjects, and were not altered after topical therapy alone. 31 As mentioned by the authors, this finding could merely indicate that the topical therapy applied was not efficacious. 31 Another study revealed that the serum levels of the soluble T-lymphocyte product interleukin-2 receptor (CD25) were statistically significantly positively correlated with the activity of psoriasis and were reduced after clinically efficacious treatment using orally administered cyclosporin A or FK506 as immunosuppressive drugs. 32 Therefore, soluble T-lymphocyte product interleukin-2 receptor (CD25) was considered to be a marker for the activity of psoriasis. 32 A subsequent study revealed that in patients with moderate to severe psoriasis (defined as the presence of PASI score >10), the peripheral blood levels of CD8+CD25+ T lymphocytes, but not CD4+CD25+ T lymphocytes, were highly statistically significantly correlated with the PASI score and therefore with the severity of psoriasis. 33 However, this statistically significant correlation was not demonstrated in patients with psoriasis of any severity (any PASI score). 33 No difference in the peripheral blood levels of CD4+CD25+ and CD8+CD25+ T lymphocytes was revealed between the psoriatic patients and the nonpsoriatic individuals. 33 According to the interpretation proposed by the authors, the severity of psoriasis could be dependent on continuous recruitment of CD8+ or CD8+CD25+ T lymphocytes from the bloodstream to the skin. 33 However, this interpretation seems not to sufficiently account either for the lack of difference in the peripheral blood levels of CD4+CD25+ and CD8+CD25+ T lymphocytes between the psoriatic patients and the nonpsoriatic individuals or for the lack of a statistically significant correlation between the peripheral blood levels of CD8+CD25+ or CD4+CD25+ T lymphocytes and the severity of psoriasis (as indicated by the PASI score) in patients with psoriasis of any severity (any A limitation of the present study was that the levels of T-lymphocyte subpopulations were examined only in the peripheral blood of patients with active chronic plaque psoriasis. It has been documented that the levels of T-lymphocyte subpopulations in the peripheral blood, i.e. at a systemic level, are not necessarily analogous to the levels of infiltrating T-lymphocyte subpopulations in psoriatic cutaneous lesions, i.e. at a topical level. For example, cells expressing the NK-cell marker CD16 were reported to be statistically significantly more in psoriatic cutaneous lesions than in cutaneous sites not affected by psoriasis, 35 but statistically significantly fewer in the peripheral blood of psoriatic patients, compared with non-psoriatic subjects. 42.06% pre-treatment), whereas NB-UVB phototherapy had no such significant impact. 36 Another study revealed comparable clinical efficacy for both treatment modalities, using the PASI score as the outcome variable. 37 At the highest level of evidence (systematic reviews), a systematic review reported a similar clinical efficacy of both therapeutic modalities, 38 whereas another systematic review concluded that NB-UVB phototherapy is a less efficacious therapeutic method than PUVA phototherapy. 9 Because of the relatively In conclusion, the present study confirms that NB-UVB phototherapy is a clinically efficacious therapeutic modality for active chronic plaque psoriasis. Although NB-UVB phototherapy has no significant effect on the levels of most T-lymphocyte subpopulations, it is associated with a significant increase in the peripheral blood levels of CD3+CD4+CD25+ T lymphocytes. The reported alterations in the peripheral blood levels of CD4+CD25+ T lymphocytes, and possibly also CD3-CD56+ and CD3-CD16+CD56+ NK cells, after NB-UVB phototherapy of active chronic plaque psoriasis could be potentially used as therapeutic outcome measures for assessing the efficacy of NB-UVB phototherapy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Fig. 2a) and after (Fig. 2b) NB-UVB phototherapy. The peripheral blood levels (%) of CD3+CD4+CD25+ T lymphocytes (depicted in yellow colour) were significantly increased after than before NB-UVB phototherapy (mean values of 18.68% versus 13.50%, respectively). In contrast, the peripheral blood levels (%) of CD3+CD8+CD25+ T lymphocytes (depicted in pink colour) were not significantly altered after NB-UVB phototherapy, compared with pre-treatment values (mean values of 0.84% versus 1.01%, respectively). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 2a . Flow cytometer photographs in a 59 year-old male smoking patient with diabetes and hyperlipidaemia before (Fig. 2a) and after (Fig. 2b) NB-UVB phototherapy. The peripheral blood levels (%) of CD3+CD4+CD25+ T lymphocytes (depicted in yellow colour) were significantly increased after than before NB-UVB phototherapy (mean values of 18.68% versus 13.50%, respectively). In contrast, the peripheral blood levels (%) of CD3+CD8+CD25+ T lymphocytes (depicted in pink colour) were not significantly altered after NB-UVB phototherapy, compared with pre-treatment values (mean values of 0.84% versus 1.01%, respectively). 48x45mm (97 x 97 DPI)
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Page 38 of 39 PHOTO -manuscript copy 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Flow cytometer photographs in a 59 year-old male smoking patient with diabetes and hyperlipidaemia before (Fig. 2a) and after (Fig. 2b) NB-UVB phototherapy. The peripheral blood levels (%) of CD3+CD4+CD25+ T lymphocytes (depicted in yellow colour) were significantly increased after than before NB-UVB phototherapy (mean values of 18.68% versus 13.50%, respectively). In contrast, the peripheral blood levels (%) of CD3+CD8+CD25+ T lymphocytes (depicted in pink colour) were not significantly altered after NB-UVB phototherapy, compared with pre-treatment values (mean values of 0.84% versus 1.01%, respectively). 56x50mm (90 x 90 DPI)
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